Skip to main content

Advertisement

SpringerLink
Log in

Is a single infusion of zoledronic acid superior to risedronate for the treatment of Paget's disease?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kanis JA (1998) Pathophysiology and Treatment of Paget's Disease of Bone, edn 2. London: Martin Dunitz Ltd

    Google Scholar 

  2. Selby PL et al. (2002) Guidelines on the management of Paget's disease of bone. Bone 31: 366–373

    Article  CAS  Google Scholar 

  3. Schweitzer DH et al. (1993) Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 8: 175–182

    Article  CAS  Google Scholar 

  4. Miller PD et al. (1999) A randomized, double-blind comparison of risedronate and etidronate in the management of Paget's disease of bone. Am J Med 106: 513–520

    Article  CAS  Google Scholar 

  5. Siris E et al. (1996) Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81: 961–967

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Marie Lofthouse, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine, Consultant Physician and Director of Bone and Mineral Research at the Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands

    Socrates E Papapoulos

Authors
  1. Socrates E Papapoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Socrates E Papapoulos.

Ethics declarations

Competing interests

SE Papapoulos has received research support and/or honoraria from all major pharmaceutical companies involved in bisphosphonate development. (Merck & Co, Novartis, Roche/GSK, Alliance for Better Bone Health- Procter & Gamble-Aventis-Sanofi)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papapoulos, S. Is a single infusion of zoledronic acid superior to risedronate for the treatment of Paget's disease?. Nat Rev Endocrinol 2, 252–253 (2006). https://doi.org/10.1038/ncpendmet0166

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0166

  • Springer Nature Limited

Search

Navigation